Joëll E. Bense

Joëll E. Bense

Auto-generated profile, based on publicly available information

Joëll E. Bense

Division of Stem cell Transplantation, Department of Pediatrics, Willem-Alexander Children’s Hospital, Leiden University Medical Center, Leiden, the Netherlands

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2022 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
LKL. C. de Kloet
L. C. de Kloet
JBJ. E. Bense
J. E. Bense
MSM. Y. E. C. van der Stoep
M. Y. E. C. van der Stoep
MLM. Louwerens
M. Louwerens
EAE. G. J. von Asmuth
E. G. J. von Asmuth
SHSabine Hannema
Sabine Hannema

30 December 2022 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
JBJoëll E. Bense
Joëll E. Bense
LHLotte Haverman
Lotte Haverman
EAErik G.J. von Asmuth
Erik G.J. von Asmuth
MLMarloes Louwerens
Marloes Louwerens
MLMichiel A.J. Luijten
Michiel A.J. Luijten
APAnne P.J. de Pagter
Anne P.J. de Pagter
Survival rates in pediatric hematopoietic stem cell transplantation (HSCT) for nonmalignant diseases have improved due to advances in conditioning regimens, donor selection, and prophylaxis and treatment of infections and graft-versus-host disease. Insight into the long-term patient-reported outcomes (PROs) after pediatric HSCT for nonmalignant disease is lacking but essential for optimal shared decision making, counseling, and quality of care. The purpose of this research was to determine long-term patient-reported outcomes in allogeneic pediatric HSCT for nonmalignant diseases and to compare these results with Dutch reference data. This single-center cohort study evaluated PROs (PedsQL 4.0, PROMIS item banks), self- or proxy-reported, among patients at ≥2 years after pediatric allogeneic HSCT for nonmalignant disease. Mean scores were compared with those of the Dutch general population. Of 171 eligible patients, 119 participated, for a 70% response rate. The median patient age was 15.8 years (range, 2 to 49 years), and the median duration of follow-up was 8.7 years (range, 2 to 34 years). Indications for HSCT included inborn errors of immunity (n = 41), hemoglobinopathies (n = 37), and bone marrow failure (n = 41). Compared with reference data, significantly lower scores were found in adolescents (age 13 to 17 years) on the Total, Physical Health, and School Functioning PedsQL subscales. Significantly more Sleep Disturbance was reported in children (age 8 to 18 years). On the other hand, significantly better scores were seen on PROMIS Fatigue (age 5 to 7 years) and Pain Interference (age 8 to 18 years) and, in adults (age 19 to 30 years), on Depressive Symptoms and Sleep Disturbance. This study showed better or comparable very long-term PROs in patients after pediatric HSCT for nonmalignant diseases compared with the reference population. Children and adolescents seem to be the most affected, indicating the need for supportive care to prevent impaired quality of life and, more importantly, to amplify their long-term well-being.

28 August 2023 in Pediatric Blood & Cancer
Verified
Journal Article
Open access
JBJoëll E. Bense
Joëll E. Bense
ASAnne M. Stiggelbout
Anne M. Stiggelbout
ALArjan C. Lankester
Arjan C. Lankester
APAnne P. J. de Pagter
Anne P. J. de Pagter
Background: Survival rates have continued to increase for pediatric hematopoietic stem cell transplantation (HSCT) for nonmalignant diseases. Despite the crucial role of caregivers in this high‐intensity treatment, knowledge about long‐term parental impact is lacking.Procedure: This cross‐sectional study assessed parental distress and everyday problems in parents of patients 2 years and older after pediatric HSCT for a nonmalignant disease using Distress Thermometer for Parents (DT‐P), and compared outcomes to matched Dutch parents of healthy children and Dutch parents of children with a chronic condition (CC).Results: Median follow‐up was 5.3 years (interquartile range [IQR]: 2.9–8.6). Underlying diseases were inborn errors of immunity (N = 30), hemoglobinopathies (N = 13), and bone marrow failure (N = 27). Mothers of pediatric HSCT recipients (N = 70) reported comparable overall distress levels to mothers of healthy children, but experienced more distress related to parenting problems, specifically managing their child's emotions, discussing disease consequences, and fostering independence. Fathers of HSCT recipients (N = 45) reported higher overall distress levels and had more emotional distress compared to fathers of healthy children.Conclusions: Overall, parental distress and everyday problems of parents of HSCT recipients are comparable to those of parents of children with CC. However, there is ongoing parental burden, both emotional and in parenting, long‐term after HSCT compared to parents of healthy children, and the type of burden differs between mothers and fathers. These results indicate that individualized parental supportive care should not remain restricted to the acute hospitalization phase, but also be actively offered during long‐term follow‐up after pediatric HSCT.

13 January 2025 in Blood Cancer Discovery
Verified
Journal Article
Open access
KMKonradin F. Müskens
Konradin F. Müskens
NWNienke Wieringa
Nienke Wieringa
MBMaaike G.J.M. van Bergen
Maaike G.J.M. van Bergen
JBJoëll E. Bense
Joëll E. Bense
BPBrigit M. Te Pas
Brigit M. Te Pas
MBMirjam Belderbos
Mirjam Belderbos
In pediatric hematopoietic cell transplantation (HCT) recipients, transplanted donor cells may need to function far beyond normal human lifespan. In this study, we investigated the risk of clonal hematopoiesis (CH) in 144 pediatric long-term HCT survivors and 258 nontransplanted controls. CH was detected in 16% of HCT recipients and 8% of controls at variant allele frequencies of 0.01 to 0.31. Mutations were predominantly in DNMT3A (80%) and TET2 (20%). Older hematopoietic age (OR: 1.07; P < 0.001) and the HCT procedure (OR: 2.53; P = 0.02) independently increased the risk of CH, indicating both aging- and transplantation-induced effects. Large clones (variant allele frequency >0.10) were found exclusively in HCT recipients. Notably, CH was also detected within 15 years after a cord blood HCT. Inflammatory processes around graft infusion were associated with CH presence. Future studies are required to track the evolution of posttransplant CH and its impact on future cardiovascular diseases, second malignancies, and overall survival. Significance: As survival of HCT recipients continues to improve, late treatment effects gain importance. We demonstrate that pediatric HCT recipients show increased risk of CH compared with age-matched controls. Prospective studies are crucial to understand the clinical implications of posttransplant CH in this young population.

15 December 2023 in Health Expectations
Verified
Journal Article
Open access
JBJoëll E. Bense
Joëll E. Bense
NGNicole Guilonard
Nicole Guilonard
FZFemke Zwaginga
Femke Zwaginga
ASAnne M. Stiggelbout
Anne M. Stiggelbout
MLMarloes Louwerens
Marloes Louwerens
APAnne P. J. de Pagter
Anne P. J. de Pagter
Introduction: The assessment of using patient‐reported outcomes (PROs) within comprehensive care follow‐up programmes, specifically focused on health screening, remains largely unexplored. PROs were implemented in our late effects and comprehensive care programme after paediatric hematopoietic stem cell transplantation (HSCT) for nonmalignant diseases. The programme focuses solely on screening of physical and mental health and on discussing PROs during the consultation.Methods: The primary method of this study was semistructured interviews to explore the perspective of both patients and healthcare providers' (HCP) on the use of PROs, which were thematically analyzed. Additionally, an explorative quantitative approach with patient‐reported experience measures (PREMS) was used, with a pretest–posttest design, to assess whether the use of PROs was accompanied by more patient‐centred care.Results: From the patient‐interviews (N = 15) four themes were extracted: use of PROs (1) help to discuss topics; (2) make the patients feel understood; (3) create a moment of self‐reflection; and (4) make consultations more efficient. Pre‐ and postimplementation analysis of PREMs (N = 40) did not show significant differences in terms of patient‐centeredness.Conclusion: Our results demonstrate the added value of integrating PROs for health screening purposes within the long‐term follow‐up programme after paediatric HSCT, as perceived by both patient and HCP. With the active use of PROs, patients are stimulated to consciously assess their health status.Patient Contribution: This study included patients as participants. Caregivers were approached if patients were below a certain age. Additionally, preliminary results were shared with all patients (including nonparticipants) during a patient conference day.

29 July 2022 in Health Expectations
Verified
Journal Article
Open access
JBJoëll E. Bense
Joëll E. Bense
LWLieke ter Welle
Lieke ter Welle
HMHilda Mekelenkamp
Hilda Mekelenkamp
MSMarieke Schimmel
Marieke Schimmel
MLMarloes Louwerens
Marloes Louwerens
APAnne P. J. de Pagter
Anne P. J. de Pagter
Introduction: An understanding of the long‐term psychosocial impact of paediatric haematopoietic stem cell transplantation (HSCT) for nonmalignant diseases is needed to optimize pre‐HSCT counselling, supportive care and long‐term follow‐up programmes after HSCT for this group of patients and caregivers.Methods: This qualitative study included 14 patients who underwent transplantation for a nonmalignant disease during childhood. In‐depth interviews were held online to explore patients' perspectives on the long‐term psychosocial impact of HSCT on their lives. The results were analysed based on the Grounded Theory approach.Results: Patients' median age at the time of the interview was 19 years (range: 14–49), and the median years after HSCT was 12 years (range: 3–33). Four main themes were identified: (1) doing okay, (2) experiencing persistent involvement with healthcare services, (3) influence on relationships with loved ones and (4) impact on the patient's life course. Subthemes extracted were doing okay, feeling of being cured, health limitations, sense of vulnerability, ongoing connection to the hospital, acceptance, friendship, family relations, development of own identity, not taking life for granted, social development, impact on (school) career and thinking about the future.Conclusions: Patients reported active coping strategies and resilience after this high‐impact treatment. The data highlight the need for patient‐adjusted supportive care, indicating more need for supportive care in the long‐term outpatient clinic.Patient Contribution: This study included patients as participants. Caregivers were approached if patients were below a certain age. Additionally, preliminary results were presented during a patient conference day.